Cellectar Biosciences, Inc.
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
CLRB | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 100 CAMPUS DRIVE, 7932 FLORHAM PARK
- Website:
- https://www.cellectar.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company's proprietary Phospholipid Drug Conjugate (PDC) platform utilizes Phospholipid Ethers (PLEs) to selectively deliver cytotoxic payloads to cancer cells. This novel approach targets the unique lipid composition of tumor cell membranes, a universal feature of malignant cells, enabling broad application across various cancer types, including primary tumors and metastases. Its lead candidate, iopofosine I-131, is a PDC in a pivotal clinical study for Waldenstrom’s macroglobulinemia and is being evaluated in multiple other cancer indications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cellectar Biosciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectar Biosciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectar Biosciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
